Cargando…

Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes

AIMS: Sacubitril/valsartan is a neprilysin‐inhibitor/angiotensin II receptor blocker used for the treatment of heart failure. Recently, a post‐hoc analysis of a 3‐year randomized controlled trial showed improved glycaemic control with sacubitril/valsartan in patients with heart failure and type 2 di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wewer Albrechtsen, Nicolai J., Møller, Andreas, Martinussen, Christoffer, Gluud, Lise L., Rashu, Elias B., Richter, Michael M., Plomgaard, Peter, Goetze, Jens P., Kjeldsen, Sasha, Hansen, Lasse Holst, Gustafsson, Finn, Deacon, Carolyn F., Holst, Jens J., Madsbad, Sten, Bojsen‐Møller, Kirstine N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545540/ https://www.ncbi.nlm.nih.gov/pubmed/35676803 http://dx.doi.org/10.1111/dom.14789

Ejemplares similares

Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy
por: Kjeldsen, Sasha A.S., et al.
Publicado: (2023)

SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy
por: Sampson Kjeldsen, Sasha Alexandra, et al.
Publicado: (2023)

Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss()
por: Holst, Jens Juul, et al.
Publicado: (2018)

Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes
por: Jørgensen, Nils B., et al.
Publicado: (2019)

Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism
por: Kjeldsen, Sasha A S, et al.
Publicado: (2021)

Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass
por: Jonsson, Isabella, et al.
Publicado: (2021)

Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine
por: Modvig, Ida M., et al.
Publicado: (2020)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Methods and Guidelines for Measurement of Glucagon in Plasma
por: Holst, Jens J., et al.
Publicado: (2019)

Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis
por: Pedersen, Julie Steen, et al.
Publicado: (2020)

Chenodeoxycholic acid stimulates glucagon‐like peptide‐1 secretion in patients after Roux‐en‐Y gastric bypass
por: Nielsen, Signe, et al.
Publicado: (2017)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake
por: Bojsen-Møller, Kirstine Nyvold, et al.
Publicado: (2023)

Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux‐en‐Y gastric bypass
por: Kazankov, Konstantin, et al.
Publicado: (2022)

Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy
por: Hedbäck, Nora, et al.
Publicado: (2022)

Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
por: Kjeldsen, Sasha A S, et al.
Publicado: (2023)

Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes
por: Jørgensen, Nils B., et al.
Publicado: (2013)

Proteomics reveals the effects of sustained weight loss on the human plasma proteome
por: Geyer, Philipp E, et al.
Publicado: (2016)

The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Health care professionals from developing countries report educational benefits after an online diabetes course
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

Glucagon Receptor Signaling and Lipid Metabolism
por: Galsgaard, Katrine D., et al.
Publicado: (2019)

The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease
por: Werge, Mikkel Parsberg, et al.
Publicado: (2021)

What is Diabetes Remission?
por: Holst, Jens J., et al.
Publicado: (2021)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies
por: Pedersen, Julie Steen, et al.
Publicado: (2021)

The Liver–α-Cell Axis in Health and in Disease
por: Richter, Michael M., et al.
Publicado: (2022)

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
por: Ronn, Jonas, et al.
Publicado: (2017)

Acute administration of interleukin‐6 does not increase secretion of glucagon‐like peptide‐1 in mice
por: Christiansen, Charlotte B., et al.
Publicado: (2018)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

On the relationship between glucose absorption and glucose‐stimulated secretion of GLP‐1, neurotensin, and PYY from different intestinal segments in the rat
por: Kuhre, Rune E., et al.
Publicado: (2017)

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

Postprandial dysfunction in fatty liver disease
por: Grandt, Josephine, et al.
Publicado: (2023)

Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas
por: Kuhre, Rune E., et al.
Publicado: (2018)

Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass Surgery
por: Li, Qing-Run, et al.
Publicado: (2018)

Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R–dependent manner
por: Jepsen, Sara L., et al.
Publicado: (2021)

GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass
por: Guimarães, Marta, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_84lduph218c3vim25r745drmd2